Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Guggenheim revised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $284 from $224 and reiterated a Buy rating on the shares following the company’s fiscal Q4 report. Krystal Biotech, Inc. (NASDAQ:KRYS) announced its fiscal Q4 and full year 2025 financial results on February 17, reporting that it recorded $107.1 million and $389.1 million in VYJUVEK net product revenue for fi ...

Longtime drug developer Suma Krishnan was in her late-40s when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder in which the skin becomes as fragile as butterfly wings. In 2016, at 51, after a few months of modeling the idea and starting the process of patenting it, she and her husband Krish Krishnan, with whom she’d worked in biotech for more than a decade, cofounded Krystal Biotech.See where she landed on the #Forbes250 America's Greatest Innovators list: https://t.co ...

Krystal Biotech, Inc. (NASDAQ:KRYS) is among the 11 Best All-Time High Stocks to Buy According to Wall Street. On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating. Roger Song noted another strong quarter and full year, with Vyjuvek and DEB U.S. revenue growth re-accelerating on robust demand and penetration reaching about 60%, while ex-U.S. expansion is expected to become a 2026 growth driver. Roger ...

Core Insights - The company's Q4 performance is attributed to successful expansion of the US sales force and initial revenue contributions from early launches in Germany, France, and Japan [1] - The US market is shifting towards a 'start-stop' treatment regime for longer-tenured patients as disease management stabilizes [1] - International expansion is identified as the primary revenue growth driver for 2026, leveraging a larger patient pool outside the US and favorable product labels [1] - The company is maintaining a disciplined capital allocation strategy, aiming to compound value through operating profitability without relying on equity dilution [1] - High gross margins of 94% were achieved through efficient manufacturing, though slightly offset by higher unit costs for initial international volumes ahead of planned optimizations [1] - Strategic positioning focuses on self-launching four potential upcoming indications and building a specialized commercial infrastructure for rare genetic medicines [1]

Core Insights - Krystal Biotech reported strong revenue growth for Q4 2025 and full-year 2025, with net revenue from VYJUVEK reaching $107.1 million in Q4 and $389.1 million for the year, representing approximately 34% year-over-year growth [3][4][6] Financial Performance - R&D expenses for Q4 2025 were $14.8 million, up from $13.5 million a year earlier, while SG&A expenses increased to $41.4 million from $31.3 million, primarily due to higher headcount and costs associated with global launches [1] - Gross margin remained strong at 94% for both the quarter and the full year, with expectations to maintain margins in the 90% to 95% range for the foreseeable future [2] Market Expansion - The company is experiencing momentum in international markets, particularly in Europe and Japan, with over 90 DEB patients prescribed VYJUVEK across these regions [13] - U.S. commercial momentum is also strong, with more than 660 reimbursement approvals and over 500 unique prescribers since launch [6][9] Pipeline Developments - Krystal is advancing multiple programs, including KB407 for cystic fibrosis, with expected registrational readouts before year-end [5][18] - Protocol changes for KB801 and KB803 aim to facilitate at-home dosing, with data expected before year-end [19][20] Cash Position - The company ended 2025 with $955.9 million in cash and investments, providing a strong financial foundation for future growth [8]

Longtime drug developer Suma Krishnan was in her late-40s when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder in which the skin becomes as fragile as butterfly wings. In 2016, at 51, after a few months of modeling the idea and starting the process of patenting it, she and her husband Krish Krishnan, with whom she’d worked in biotech for more than a decade, cofounded Krystal Biotech.See where she landed on the #Forbes250 America's Greatest Innovators list: https://t.co ...

Longtime drug developer Suma Krishnan was in her late-40s when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder in which the skin becomes as fragile as butterfly wings. In 2016, at 51, after a few months of modeling the idea and starting the process of patenting it, she and her husband Krish Krishnan, with whom she’d worked in biotech for more than a decade, cofounded Krystal Biotech.See where she landed on the #Forbes250 America's Greatest Innovators list: https://t.co ...

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as one of the top 10 growth stocks on NASDAQ for the next decade, with multiple analysts raising their price targets significantly, indicating strong future potential [1][3][5] Price Target Adjustments - Goldman Sachs raised its price target from $206 to $327, suggesting a 16.7% upside from current levels [1] - Clear Street increased its price target from $288 to $338, indicating a further 20.7% upside [3] - Bank of America adjusted its price target from $288 to $318, reflecting a 13.8% upside [5] Growth Programs - The company is focusing on short-term growth through three registrational programs: KB801, KB803, and KB407, with potential product launches expected around 2028 [1] - Ophthalmic programs are viewed as de-risked and scalable, leveraging the existing Vyjuvek commercial platform [2] Market Opportunities - KB407 is seen as a promising opportunity in cystic fibrosis, with long-term potential contingent on additional FEV1 data [2] - The neurotrophic keratitis market is a significant source of investor interest, particularly driven by KB801, which contributed to the upward revision of price targets [4] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs, with products including VYJUVEK, KB105, KB104, KB407, and KB707 [6]

Core Insights - Kymera Therapeutics (KYMR) has initiated patient dosing in the phase IIb BREADTH study for KT-621, targeting moderate-to-severe eosinophilic asthma, with top-line data expected in late 2027 [1][6] - KT-621 is a first-in-class oral degrader of STAT6, which plays a crucial role in IL-4/IL-13 signaling and type II inflammation [1][3] - The study aims to address the significant unmet need for effective asthma treatments, as current options are limited to inhalers and injectable biologics [2][3] Study Details - The BREADTH study is a randomized, dose-ranging trial involving approximately 264 adults over 12 weeks, assessing three doses of KT-621 [4] - Primary endpoint is the change in forced expiratory volume in one second (FEV1) from baseline, with secondary endpoints focusing on additional efficacy, safety, tolerability, and quality of life [4] - Eligibility criteria include a blood eosinophil count of at least 300 cells/µL and pre-bronchodilator FEV1 between 40% and 80% of predicted normal [4] Market Performance - Over the past six months, Kymera Therapeutics' stock has increased by 68.9%, outperforming the industry growth of 22.7% [5] Additional Indications - KT-621 is also being evaluated for atopic dermatitis (AD), with positive phase Ib BroADen study results showing significant STAT6 degradation and reductions in disease-relevant biomarkers [9][10] - A concurrent phase IIb BROADEN2 study for AD is underway, expecting to report data by mid-2027 [11][12] - The dual focus on asthma and AD is intended to expedite KT-621's development and support dose selection for future phase III studies [12]

Core Insights - Biogen has received FDA Breakthrough Therapy designation for its investigational drug litifilimab (BIIB059) aimed at treating cutaneous lupus erythematosus (CLE) [1][5] Group 1: FDA Breakthrough Therapy Designation - The FDA's Breakthrough Therapy designation accelerates the development and review of drugs for serious conditions, granted when early clinical evidence indicates significant improvement over existing treatments [2] - This designation provides drugs with enhanced guidance and support from senior FDA management [2] Group 2: Clinical Evidence and Current Treatments - The FDA's decision was backed by evidence from the phase II LILAC study, which showed that litifilimab significantly reduced skin disease activity in CLE patients compared to placebo [3][5] - Current treatments for CLE, such as topical steroids and immunosuppressants, primarily manage symptoms without modifying disease progression [3] Group 3: Ongoing Studies and Future Prospects - Biogen is conducting a phase III AMETHYST study for litifilimab, with data expected in 2027, alongside two other studies for systemic lupus erythematosus (SLE) [7] - The company has additional late-stage candidates in its immunology pipeline, including dapirolizumab pegol for active SLE and felzartamab for multiple indications [8][9] Group 4: Strategic Partnerships - Biogen has entered a research agreement with Dayra Therapeutics to enhance its immunology pipeline with a new class of oral therapies, aiming to improve patient convenience and adherence [10][12]